MMS Form 4: Ilene Baylinson awarded 7,409 MAXIMUS RSUs

Rhea-AI Filing Summary

MAXIMUS, Inc. (MMS) reported an equity award to a company officer on a Form 4. General Manager – Health & Human, Ilene Baylinson, received a grant of 7,409 restricted stock units (RSUs) of MAXIMUS common stock on 11/24/2025 at a stated price of $0, reflecting the nature of the award rather than a market purchase.

The RSUs vest in three equal annual installments on 09/30/2026, 09/30/2027, and 09/30/2028, subject to possible deferred vesting at the individual’s election as permitted by the award terms. Each RSU represents a contingent right to receive one share of common stock. Following this grant, Baylinson beneficially owns 21,549.135 shares of MAXIMUS common stock in direct ownership.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Baylinson Ilene R.

(Last) (First) (Middle)

C/O MAXIMUS INC.

1600 TYSONS BLVD, STE 1400

(Street)

MCLEAN VA 22102

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MAXIMUS, INC. [ MMS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Mgr - Health & Human

3. Date of Earliest Transaction (Month/Day/Year)
11/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/24/2025		A		7,409(1)	A	$0	21,549.135	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock units ("RSUs"), which vest based upon the following schedule, subject to deferred vesting for a longer period of the election of the individual, as permitted by the terms of the award: A 3-year ratable vest that occurs on 09/30/2026, 09/30/2027, and 09/30/2028. Each RSU represents a contingent right to receive one share of common stock.

	/s/ John T Martinez: As Attorney-In-Fact for: Ilene Baylinson	11/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock award did MAXIMUS (MMS) report for Ilene Baylinson?

MAXIMUS reported that Ilene Baylinson, General Manager – Health & Human, received a grant of 7,409 restricted stock units (RSUs) of MAXIMUS common stock on 11/24/2025.

How do the new MAXIMUS (MMS) RSUs for Ilene Baylinson vest?

The 7,409 RSUs vest on a 3-year ratable schedule, with vesting dates on 09/30/2026, 09/30/2027, and 09/30/2028, subject to possible deferred vesting at her election under the award terms.

What does each RSU granted by MAXIMUS (MMS) to Ilene Baylinson represent?

Each RSU represents a contingent right to receive one share of MAXIMUS common stock, subject to the vesting conditions described in the award.

What is Ilene Baylinson’s beneficial ownership in MAXIMUS (MMS) after the RSU grant?

After the reported transaction, Ilene Baylinson beneficially owns 21,549.135 shares of MAXIMUS common stock in direct ownership.

Was the MAXIMUS (MMS) RSU transaction reported as an acquisition or disposition?

The Form 4 lists the RSU-related common stock entry as an acquisition (A) of securities, consistent with an equity award rather than a market sale.

What price was reported for the MAXIMUS (MMS) RSU-related common stock entry?

The Form 4 reports a price of $0 for the common stock entry associated with the 7,409 RSUs, reflecting that this was a grant of equity, not an open-market purchase.